135 related articles for article (PubMed ID: 9315112)
1. A comparative study of normal B cells and the EBV-positive Burkitt's lymphoma cell line, Raji, as activators of the complement system.
Marquart HV; Olesen EH; Johnson AA; Damgaard G; Leslie RG
Scand J Immunol; 1997 Sep; 46(3):246-53. PubMed ID: 9315112
[TBL] [Abstract][Full Text] [Related]
2. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
Olesen EH; Johnson AA; Damgaard G; Leslie RG
Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
[TBL] [Abstract][Full Text] [Related]
3. Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines.
Cohen JH; Fischer E; Kazatchkine MD; Lenoir GM; Lefevre-Delvincourt C; Revillard JP
Scand J Immunol; 1987 Jun; 25(6):587-98. PubMed ID: 3037684
[TBL] [Abstract][Full Text] [Related]
4. Structure and functions of gp 140, the C3d/EBV receptor (CR2) of human B lymphocytes.
Frade R
Mol Immunol; 1986 Nov; 23(11):1249-53. PubMed ID: 2950318
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
6. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
7. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
8. Studies of the Epstein Barr virus receptor found on Raji cells. II. A comparison of lymphocyte binding sites for Epstein Barr virus and C3d.
Hutt-Fletcher LM; Fowler E; Lambris JD; Feighny RJ; Simmons JG; Ross GD
J Immunol; 1983 Mar; 130(3):1309-12. PubMed ID: 6218205
[TBL] [Abstract][Full Text] [Related]
9. Evidence for three binding sites for C3 (hemolytically inactive), C3b and C3d on a CR2-positive Burkitt lymphoma-derived cell line (Raji).
Barile G; Di Renzo L; Lipari M; Frati L; Faggioni A
FEBS Lett; 1993 Jun; 324(3):319-24. PubMed ID: 8405374
[TBL] [Abstract][Full Text] [Related]
10. A comparative evaluation of receptor reactivities for C3b, iC3b, and C3d on Raji lymphoblastoid cells.
Scheiner O; Hammann KP; Schmid HU; Schulz T; Alsenz J; Dierich MP
Int Arch Allergy Appl Immunol; 1982; 69(3):231-7. PubMed ID: 6215359
[TBL] [Abstract][Full Text] [Related]
11. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
12. Detection of complement receptors 1 and 2 on mouse splenic B cells using flow cytometry.
Donius LR; Weis JH
Methods Mol Biol; 2014; 1100():305-10. PubMed ID: 24218269
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
14. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
[TBL] [Abstract][Full Text] [Related]
15. Events related to Epstein-Barr virus binding and superinfection of Raji cells.
Barile G; Di Certo MG; Cirone M; Frati L; Pontieri GM; Faggioni A; Di Renzo L
Intervirology; 1994; 37(5):245-51. PubMed ID: 7698879
[TBL] [Abstract][Full Text] [Related]
16. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
17. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
[TBL] [Abstract][Full Text] [Related]
18. The Epstein-Barr virus receptor is distinct from the C3 receptor.
Wells A; Koide N; Stein H; Gerdes J; Klein G
J Gen Virol; 1983 Feb; 64 (Pt 2)():449-53. PubMed ID: 6300295
[TBL] [Abstract][Full Text] [Related]
19. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
20. Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells.
Thornton BP; Vetvicka V; Ross GD
Clin Exp Immunol; 1996 Jun; 104(3):531-7. PubMed ID: 9099940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
